UPMC Enterprises

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain. The company aims to target pain at its source to provide effective, rapid-acting pain relief without the risk of addiction. Their lead program targets Nav1.8, a validated human pain target, leveraging internal ion channel expertise.

Percipio Health is a healthcare technology company that leverages artificial intelligence to enhance patient care. It provides a platform that integrates advanced computer vision software to monitor and assess patient health status. This technology enables clinicians and caregivers to maintain a comprehensive view of a patient's well-being and accurately identify medications. By offering AI-driven insights, Percipio Health empowers healthcare providers to make informed decisions, ultimately improving the quality of care delivered to patients.

Ouroboros Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic immune-mediated illnesses. It specializes in developing immune reset treatments, using a therapeutic platform that employs T cell engager antibodies to target and deplete specific pathogenic cells. This approach aims to provide extended remissions for patients, without the need for ongoing immunosuppression. The company's strength lies in its integration of scientific knowledge and proven track record in progressing cell-depleting treatments through clinical trials, supported by a robust pipeline.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Pip Care is a healthcare company that specializes in enhancing the surgical experience through its personalized surgical journey platform. This platform collaborates with health systems to streamline the perioperative care process, supporting both care teams and patients from the preparation phase through recovery. Pip Care offers a perioperative care app that assists patients in preparing for surgery and facilitates their recovery, featuring certified health coaches who develop individualized care plans. These plans include daily tasks and tailored advice, helping patients manage appointments and feel more empowered and prepared for their surgical procedures. By focusing on the digitization and automation of existing perioperative workflows, Pip Care aims to improve surgical outcomes for patients while also enhancing the financial performance of health systems.

Medicom Technologies, Inc. is a technology company based in Raleigh, North Carolina, that specializes in improving patient care through innovative health information solutions. The company addresses interoperability challenges in healthcare by providing a network that consolidates a patient's complete medical history into an easily navigable interface. This network eliminates the need for traditional methods of sharing clinical information, such as faxes and CD-ROMs, by connecting over 2,000 healthcare organizations through more than 3,500 unique connections. Medicom offers several key products, including Imagex, a diagnostic image transfer solution; Endpoint, an image archiving system; and Hex, a patient record exchange network. Additionally, the company features the deepMed Marketplace, which supports healthcare data consumers in life sciences and pharmaceuticals by facilitating the curation of extensive longitudinal data sets for research and AI applications. Founded by Michael Rosenberg, Malcolm Benitz, and Chase Ballard, Medicom is dedicated to transforming how healthcare information is shared and utilized.

BrainCheck, Inc. is a Houston-based company that specializes in cognitive health solutions for healthcare and athletic organizations across the United States. Established in 2013, BrainCheck offers a comprehensive application designed to assist individuals in making informed decisions regarding their cognitive health. This application includes a screening tool and interactive tests that can be accessed on mobile devices or browsers, allowing users to evaluate their brain health and receive immediate results. The platform facilitates connections between patients and care teams, particularly in the concussion and dementia markets, enabling clinicians to monitor significant changes in cognitive health and share results efficiently.

Helexva operates as a biotech company that specializes in treatment for fatal neurodegenerative diseases.

Elektra Health is a digital healthcare platform designed to support women navigating perimenopause and menopause, addressing the significant disruptions these life stages can cause. With a focus on education and community, Elektra aims to eliminate the stigma surrounding hormonal changes and menopause. The platform offers access to telemedicine services provided by board-certified clinicians, along with an evidence-based educational program and a private community for women. By providing these resources, Elektra empowers women to take control of their health and well-being during this critical phase of life, as many women currently face inadequate care despite experiencing challenging symptoms such as anxiety, depression, and joint pain.

Sudo Biosciences is a biopharmaceutical company focused on designing and developing innovative medicines that target the tyrosine kinase 2 (TYK2) pseudokinase domain. This domain plays a vital role in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. Sudo Biosciences has a pipeline of next-generation TYK2 inhibitors, including a candidate aimed at treating multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation, as well as a topical treatment for immune-mediated dermatologic diseases. The company's mission is to provide effective therapies for patients at competitive costs, thereby transforming their lives and addressing unmet medical needs.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Sempre Health, Inc. is a healthcare technology company that operates a behavior-based healthcare pricing platform aimed at making prescription medications more affordable for patients. Founded in 2015 and based in San Francisco, the company collaborates with health plans and pharmaceutical manufacturers to dynamically adjust patients' co-payments based on their adherence to prescribed medications. By analyzing prescription records and individual patient behaviors, Sempre Health predicts the optimal price for medications at the point of sale. Patients receive personalized SMS notifications detailing potential discounts and guidance on improving their health, thereby encouraging timely prescription refills. This innovative approach not only enhances patient access to necessary medications but also contributes to better clinical outcomes while reducing overall healthcare costs. Additionally, Sempre Health is building a unique dataset on patient price sensitivities and cost behaviors to further refine its services.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Mozart Therapeutics is a biotechnology startup dedicated to developing innovative therapies for autoimmune and inflammatory diseases. The company specializes in creating disease-modifying CD8 T cell modulators, leveraging a unique regulatory CD8 T cell network to target a specific subset of T lymphocytes. These modulators aim to restore immune balance and mitigate the damage caused by autoreactive and pathogenic immune responses. By focusing on first-in-class CD8 Treg modulators, Mozart Therapeutics seeks to delay the onset and improve the management of various autoimmune disorders, thereby providing healthcare professionals with advanced treatment options for their patients.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative gene therapies utilizing its proprietary Anellovector platform. This platform, based on the human commensal virome, addresses several limitations of existing gene therapies, including restricted access to diverse tissues, challenges in redosing, risks of genomic integration, and issues with tolerability. Founded in 2017 and previously known as VL46, Inc., Ring Therapeutics aims to expand the applications of gene therapy beyond traditional gene replacement. By enabling a broader range of therapeutic modalities and mechanisms, the company seeks to treat a variety of previously inaccessible diseases, including genetic disorders, ophthalmology, oncology, and metabolic conditions.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Founded in 2016 and headquartered in Boston, Massachusetts, with a branch in Cambridge, United Kingdom, Cerevance utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, within mature human brain tissue. By leveraging a substantial repository of over 15,000 human brain samples, the company generates extensive expression and epigenetic data, guiding the identification of promising therapeutic targets. This approach aims to address the early onset of central nervous system diseases by revealing critical transcriptional and epigenetic differences within affected brain regions.

Clearsense, LLC is a healthcare technology company based in Jacksonville, Florida, founded in 2013. The company specializes in providing a cloud-based data platform that offers healthcare analytics and data management solutions for organizations and patients. Its platform, known as the Clearsense Data Management Platform, aggregates and manages data from various sources, facilitating real-time insights into clinical, operational, and financial metrics. By converting disparate data into a single source of truth, Clearsense enhances data maturity and optimizes analytics tools, ultimately improving decision-making and driving meaningful outcomes. The platform is designed to be secure and scalable, empowering healthcare organizations to leverage their data effectively, reduce costs, and seize new revenue opportunities.

Smile Digital Health is a health information technology company that focuses on providing data fabric solutions tailored for the healthcare sector. The company develops fast, secure, and compliant data infrastructures designed to support the complex data needs of healthcare organizations. Its enterprise-grade, open-framework platform facilitates the digital transformation of healthcare by enabling seamless collaboration and integration across various systems. This allows organizations to effectively ingest, transform, store, analyze, and share health information, ultimately enhancing patient care and driving value creation throughout the healthcare ecosystem.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Redesign Health is a company founded in 2018 that focuses on driving innovation in the healthcare sector. It develops technologies, tools, and insights designed to lower barriers to change within the industry. Redesign Health collaborates with exceptional founders to create and support over two dozen companies that have collectively impacted more than ten million lives across various healthcare domains, including cancer care, teleradiology, COVID-19 testing, and metabolic health. By fostering the growth of diverse healthcare solutions, Redesign Health aims to enhance the overall efficiency and effectiveness of healthcare delivery.

Abridge is a healthcare technology company focused on enhancing communication between patients and clinicians through its innovative application. By leveraging generative AI and machine learning, Abridge automates the transcription and summarization of medical discussions, transforming these conversations into structured clinical notes in real-time. This functionality facilitates better patient understanding and reduces the necessity for manual note-taking, while ensuring that essential documentation is incorporated into Electronic Health Record systems. The platform is designed to provide users with clear, understandable summaries of their medical interactions, empowering them to follow through on recommendations made by healthcare providers. Committed to data security and patient privacy, Abridge adheres to healthcare regulations and offers a customizable interface tailored to meet diverse patient needs.

Novasenta is a pharmaceutical company focused on developing innovative immunotherapy treatments for cancer. Founded in 2018 and headquartered in Pittsburgh, Pennsylvania, the company employs a systematic and rigorous approach to analyze human tumor microenvironments, aiming to uncover new druggable targets. By utilizing single-cell level analysis of high-quality human tumor samples and advanced data mining techniques, Novasenta accelerates the transition from discovery to patient-ready therapies. The company specializes in immuno-oncology therapeutics, leveraging a machine-learning-enabled platform to identify immune networks and potential drug targets within the tumor microenvironment. Through its research efforts, Novasenta seeks to provide patients with safer and more effective cancer treatments.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Moxe Health specializes in facilitating the exchange of clinical data between health plans and provider systems. Its platform, Substrate, enables real-time, bi-directional data transfer, including clinical, analytic, and administrative information. Moxe's solutions cover risk adjustment, quality metrics (like HEDIS and Star ratings), claims management, and care gap management, ensuring health plans and providers have the necessary data for value-based care. The company's neutrality allows seamless integration with existing systems, maximizing investments in population health and analytics.

Hashed Health is a collaborative healthcare innovation firm dedicated to leveraging blockchain and distributed ledger technologies to address challenges within the healthcare sector. The company operates a venture studio that partners with healthcare and life sciences enterprises to develop new business models through collaboration. Hashed Health focuses on creating an ecosystem of businesses that utilize blockchain infrastructure to facilitate the exchange of clinical, financial, and real-world data. Its initiatives include asset exchanges, multi-party business process automation, and data custody, enabling organizations to work together on complex problems that cannot be solved in isolation. The firm has a proven track record in healthcare spin-outs, which include innovations like professional credentials exchange and peer supply, allowing workgroups to concentrate on blockchain applications that tackle prevalent issues in healthcare.

BrainCheck, Inc. is a Houston-based company that specializes in cognitive health solutions for healthcare and athletic organizations across the United States. Established in 2013, BrainCheck offers a comprehensive application designed to assist individuals in making informed decisions regarding their cognitive health. This application includes a screening tool and interactive tests that can be accessed on mobile devices or browsers, allowing users to evaluate their brain health and receive immediate results. The platform facilitates connections between patients and care teams, particularly in the concussion and dementia markets, enabling clinicians to monitor significant changes in cognitive health and share results efficiently.

Smile Digital Health is a health information technology company that focuses on providing data fabric solutions tailored for the healthcare sector. The company develops fast, secure, and compliant data infrastructures designed to support the complex data needs of healthcare organizations. Its enterprise-grade, open-framework platform facilitates the digital transformation of healthcare by enabling seamless collaboration and integration across various systems. This allows organizations to effectively ingest, transform, store, analyze, and share health information, ultimately enhancing patient care and driving value creation throughout the healthcare ecosystem.

Ring Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative gene therapies utilizing its proprietary Anellovector platform. This platform, based on the human commensal virome, addresses several limitations of existing gene therapies, including restricted access to diverse tissues, challenges in redosing, risks of genomic integration, and issues with tolerability. Founded in 2017 and previously known as VL46, Inc., Ring Therapeutics aims to expand the applications of gene therapy beyond traditional gene replacement. By enabling a broader range of therapeutic modalities and mechanisms, the company seeks to treat a variety of previously inaccessible diseases, including genetic disorders, ophthalmology, oncology, and metabolic conditions.

Sempre Health, Inc. is a healthcare technology company that operates a behavior-based healthcare pricing platform aimed at making prescription medications more affordable for patients. Founded in 2015 and based in San Francisco, the company collaborates with health plans and pharmaceutical manufacturers to dynamically adjust patients' co-payments based on their adherence to prescribed medications. By analyzing prescription records and individual patient behaviors, Sempre Health predicts the optimal price for medications at the point of sale. Patients receive personalized SMS notifications detailing potential discounts and guidance on improving their health, thereby encouraging timely prescription refills. This innovative approach not only enhances patient access to necessary medications but also contributes to better clinical outcomes while reducing overall healthcare costs. Additionally, Sempre Health is building a unique dataset on patient price sensitivities and cost behaviors to further refine its services.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Butterfly Network, Inc. is a medical imaging company based in Guilford, Connecticut, that specializes in handheld ultrasound technology. Founded in 2011, the company has developed the world's first handheld, single-probe whole-body ultrasound system, known as Butterfly iQ, powered by its proprietary Ultrasound-on-Chip technology. This innovative device provides diagnostic imaging for various medical conditions affecting the cardiac, abdominal, urological, fetal, gynecological, and musculoskeletal systems. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion people globally who lack access to ultrasound services. By integrating cloud-connected software with its ultrasound hardware, Butterfly enhances the clinical workflow, facilitating earlier detection and remote management of health conditions.

Moxe Health specializes in facilitating the exchange of clinical data between health plans and provider systems. Its platform, Substrate, enables real-time, bi-directional data transfer, including clinical, analytic, and administrative information. Moxe's solutions cover risk adjustment, quality metrics (like HEDIS and Star ratings), claims management, and care gap management, ensuring health plans and providers have the necessary data for value-based care. The company's neutrality allows seamless integration with existing systems, maximizing investments in population health and analytics.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Founded in 2016 and headquartered in Boston, Massachusetts, with a branch in Cambridge, United Kingdom, Cerevance utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, within mature human brain tissue. By leveraging a substantial repository of over 15,000 human brain samples, the company generates extensive expression and epigenetic data, guiding the identification of promising therapeutic targets. This approach aims to address the early onset of central nervous system diseases by revealing critical transcriptional and epigenetic differences within affected brain regions.

Carta Healthcare, Inc. is a technology company that specializes in developing a software-as-a-service platform aimed at improving hospital patient management. Founded in 2016 and headquartered in San Mateo, California, the company leverages data from existing IT systems to map the patient journey through hospitals. Its platform utilizes machine learning to identify similarities between current patients and past patients, allowing healthcare providers to personalize care based on individual needs. Additionally, it predicts potential bottlenecks, such as recovery bed shortages and cancellations, offering alerts that help hospitals optimize their operations. By combining artificial intelligence with human expertise, Carta Healthcare enhances the efficiency and quality of healthcare data management, ultimately aiming to provide a better experience for patients.